
    
      The trial is an open-label, multi-center, safety trial of GEN1042. The trial consists of two
      parts, a dose escalation (phase 1, first-in-human (FIH) and an expansion part (Phase 2a). The
      expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has
      been determined.
    
  